Amendment: SEC Form SC 13G/A filed by Aclaris Therapeutics Inc.

11/14/24 4:14:52 PM ET

$ACRS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ACRS alert in real time by email

SC 13G/A 1 tm2427061d1_sc13ga.htm SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G*

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO § 240.13d-2

(Amendment No. 2)*

Aclaris Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.00001 par value per share (the “Shares”)

(Title of Class of Securities)

00461U105

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of the Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o	Rule 13d-1(b)
x	Rule 13d-1(c)
o	Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 00461U105

13G

Page 2 of 13 Pages

1.	NAME OF REPORTING PERSONS Citadel Advisors LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o (b) o
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5.	SOLE VOTING POWER 0
		6.	SHARED VOTING POWER 236,249 Shares
		7.	SOLE DISPOSITIVE POWER 0
		8.	SHARED DISPOSITIVE POWER See Row 6 above
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.3%¹
12.	TYPE OF REPORTING PERSON IA; OO; HC

_________________________

¹	The percentages reported in this Schedule 13G are based upon 71,344,557 Shares outstanding as of July 31, 2024 (according to the issuer’s Form 10-Q as filed with the Securities and Exchange Commission on August 7, 2024).

CUSIP No. 00461U105

13G

Page 3 of 13 Pages

1.	NAME OF REPORTING PERSONS Citadel Advisors Holdings LP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o (b) o
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5.	SOLE VOTING POWER 0
		6.	SHARED VOTING POWER 236,249 Shares
		7.	SOLE DISPOSITIVE POWER 0
		8.	SHARED DISPOSITIVE POWER See Row 6 above
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.3%
12.	TYPE OF REPORTING PERSON PN; HC

CUSIP No. 00461U105

13G

Page 4 of 13 Pages

1.	NAME OF REPORTING PERSONS Citadel GP LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o (b) o
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5.	SOLE VOTING POWER 0
		6.	SHARED VOTING POWER 236,249 Shares
		7.	SOLE DISPOSITIVE POWER 0
		8.	SHARED DISPOSITIVE POWER See Row 6 above
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.3%
12.	TYPE OF REPORTING PERSON OO; HC

CUSIP No. 00461U105

13G

Page 5 of 13 Pages

1.	NAME OF REPORTING PERSONS Citadel Securities LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o (b) o
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5.	SOLE VOTING POWER 0
		6.	SHARED VOTING POWER 3,500 Shares
		7.	SOLE DISPOSITIVE POWER 0
		8.	SHARED DISPOSITIVE POWER See Row 6 above
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.0%
12.	TYPE OF REPORTING PERSON BD; OO

CUSIP No. 00461U105

13G

Page 6 of 13 Pages

1.	NAME OF REPORTING PERSONS Citadel Securities Group LP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o (b) o
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5.	SOLE VOTING POWER 0
		6.	SHARED VOTING POWER 131,818 Shares
		7.	SOLE DISPOSITIVE POWER 0
		8.	SHARED DISPOSITIVE POWER See Row 6 above
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.2%
12.	TYPE OF REPORTING PERSON PN; HC

CUSIP No. 00461U105

13G

Page 7 of 13 Pages

1.	NAME OF REPORTING PERSONS Citadel Securities GP LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o (b) o
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5.	SOLE VOTING POWER 0
		6.	SHARED VOTING POWER 131,818 Shares
		7.	SOLE DISPOSITIVE POWER 0
		8.	SHARED DISPOSITIVE POWER See Row 6 above
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.2%
12.	TYPE OF REPORTING PERSON OO; HC

CUSIP No. 00461U105

13G

Page 8 of 13 Pages

1.	NAME OF REPORTING PERSONS Kenneth Griffin
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o (b) o
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION U.S. Citizen
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5.	SOLE VOTING POWER 0
		6.	SHARED VOTING POWER 368,067 Shares
		7.	SOLE DISPOSITIVE POWER 0
		8.	SHARED DISPOSITIVE POWER See Row 6 above
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.5%
12.	TYPE OF REPORTING PERSON IN; HC

CUSIP No. 00461U105

13G

Page 9 of 13 Pages

Item 1(a).	Name of Issuer:

	Aclaris Therapeutics, Inc.

Item 1(b).	Address of Issuer’s Principal Executive Offices:

	701 Lee Road, Suite 103, Wayne, PA 19087

Item 2(a).	Name of Person Filing:

	This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), Citadel Securities Group LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to the Shares of the above-named issuer owned by Citadel Quantitative Strategies Master Fund Ltd., a Cayman Islands company (“QSMF”), CRBU Holdings LLC, a Delaware limited liability company (“CRBH”), and Citadel Securities. Such owned Shares may include other instruments exercisable for or convertible into Shares.

	Citadel Advisors is the portfolio manager for QSMF. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of CRBH and Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.

	The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

Item 2(b).	Address or Principal Business Office or, if none, Residence:

	The address of each of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.

Item 2(c).	Citizenship:

	Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.

Item 2(d).	Title of Class of Securities:

	Common Stock, $0.00001 par value per share

Item 2(e).	CUSIP Number:

	00461U105

CUSIP No. 00461U105

13G

Page 10 of 13 Pages

Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

	(a)	¨	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
	(b)	¨	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
	(c)	¨	Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
	(d)	¨	Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
	(e)	¨	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
	(f)	¨	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
	(g)	¨	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
	(h)	¨	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	¨	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
	(j)	¨	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
	(k)	¨	Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

	If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

Item 4.	Ownership:

	A.	Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC

		(a)	Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 236,249 Shares.

		(b)	The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 0.3% of the Shares outstanding.

		(c)	Number of Shares as to which such person has:

			(i)	sole power to vote or to direct the vote: 0

			(ii)	shared power to vote or to direct the vote: 236,249

			(iii)	sole power to dispose or to direct the disposition of: 0

			(iv)	shared power to dispose or to direct the disposition of: 236,249

CUSIP No. 00461U105

13G

Page 11 of 13 Pages

B.	Citadel Securities LLC

	(a)	Citadel Securities LLC may be deemed to beneficially own 3,500 Shares.

	(b)	The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding.

	(c)	Number of shares of Shares as to which such person has:

		(i)	sole power to vote or to direct the vote: 0

		(ii)	shared power to vote or to direct the vote: 3,500

		(iii)	sole power to dispose or to direct the disposition of: 0

		(iv)	shared power to dispose or to direct the disposition of: 3,500

C.	Citadel Securities Group LP and Citadel Securities GP LLC

	(a)	Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 131,818 Shares.

	(b)	The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.2% of the Shares outstanding.

	(c)	Number of Shares as to which such person has:

		(i)	sole power to vote or to direct the vote: 0

		(ii)	shared power to vote or to direct the vote: 131,818

		(iii)	sole power to dispose or to direct the disposition of: 0

		(iv)	shared power to dispose or to direct the disposition of: 131,818

CUSIP No. 00461U105

13G

Page 12 of 13 Pages

D.	Kenneth Griffin

	(a)	Mr. Griffin may be deemed to beneficially own 368,067 Shares.

	(b)	The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 0.5% of the Shares outstanding.

	(c)	Number of Shares as to which such person has:

		(i)	sole power to vote or to direct the vote: 0

		(ii)	shared power to vote or to direct the vote: 368,067

		(iii)	sole power to dispose or to direct the disposition of: 0

		(iv)	shared power to dispose or to direct the disposition of: 368,067

Item 5.	Ownership of Five Percent or Less of a Class:

	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. x

Item 6.	Ownership of More Than Five Percent on Behalf of Another Person:

	Not Applicable

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

	Not Applicable

Item 8.	Identification and Classification of Members of the Group:

	Not Applicable

Item 9.	Notice of Dissolution of Group:

	Not Applicable

Item 10.	Certifications:

	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 00461U105

13G

Page 13 of 13 Pages

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated November 14, 2024.

CITADEL SECURITIES LLC		CITADEL ADVISORS LLC

By:	/s/ Guy Miller	By:	/s/ Seth Levy
	Guy Miller, Authorized Signatory		Seth Levy, Authorized Signatory


CITADEL SECURITIES GROUP LP		CITADEL ADVISORS HOLDINGS LP

By:	/s/ Guy Miller	By:	/s/ Seth Levy
	Guy Miller, Authorized Signatory		Seth Levy, Authorized Signatory


CITADEL SECURITIES GP LLC		CITADEL GP LLC

By:	/s/ Guy Miller	By:	/s/ Seth Levy
	Guy Miller, Authorized Signatory		Seth Levy, Authorized Signatory


		KENNETH GRIFFIN

		By:	/s/ Seth Levy
			Seth Levy, attorney-in-fact*

_________________________

Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.

Get the next $ACRS alert in real time by email

Date	Price Target	Rating	Analyst
3/18/2025		Overweight	Cantor Fitzgerald
12/23/2024	$20.00	Neutral → Buy	H.C. Wainwright
11/20/2024		Neutral → Overweight	Cantor Fitzgerald
11/19/2024	$2.00 → $7.00	Market Perform → Outperform	Leerink Partners
11/19/2024	$8.00	Neutral → Buy	BTIG Research
11/19/2024	$2.00 → $7.00	Hold → Buy	Jefferies
11/18/2024	$3.00 → $13.00	Neutral → Overweight	Piper Sandler
1/22/2024		Buy → Neutral	H.C. Wainwright

Amendment: SEC Form SC 13G/A filed by Aclaris Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for $ACRS

$ACRS Press Releases

Fastest customizable press release news feed in the world

Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

$ACRS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Mehra Anand bought $1,499,998 worth of shares (666,666 units at $2.25), increasing direct ownership by 1,537% to 710,030 units (SEC Form 4)

Large owner Leonard Braden Michael bought $472,757 worth of shares (373,569 units at $1.27) (SEC Form 4)

Large owner Leonard Braden Michael bought $359,010 worth of shares (273,730 units at $1.31) (SEC Form 4)

$ACRS Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Aclaris Therapeutics Inc.

SEC Form SC 13G filed by Aclaris Therapeutics Inc.

SEC Form SC 13G filed by Aclaris Therapeutics Inc.

$ACRS Leadership Updates

Live Leadership Updates

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Aclaris Therapeutics Announces Key Leadership Transitions

$ACRS Financials

Live finance-specific insights

$ACRS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$ACRS SEC Filings

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Cantor Fitzgerald resumed coverage on Aclaris Therapeutics

Aclaris Therapeutics upgraded by H.C. Wainwright with a new price target

Aclaris Therapeutics upgraded by Cantor Fitzgerald

SEC Form 10-Q filed by Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form SCHEDULE 13G filed by Aclaris Therapeutics Inc.

$ACRS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Medical Officer Hall Jesse Wayne

SEC Form 3 filed by new insider Hall Jesse Wayne

CEO Walker Neal converted options into 9,467 shares and covered exercise/tax liability with 2,975 shares, increasing direct ownership by 0.44% to 1,479,824 units (SEC Form 4)

Recent Analyst Ratings for
$ACRS

$ACRS
Press Releases

$ACRS
Insider Purchases

$ACRS
Large Ownership Changes

$ACRS
Leadership Updates

$ACRS
Financials

$ACRS
Analyst Ratings

$ACRS
SEC Filings

$ACRS
Insider Trading